A combination of models for end-stage liver disease and cirrhosis-related complications to predict the prognosis of liver cirrhosis - 28/11/12
Corresponding author. Tel.: +139 023 83 232.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background |
The Child-Pugh score, the model for end-stage liver disease (MELD) score, and the occurrence of cirrhosis-related complications are independent prognostic predictors used in the assessment of chronic liver diseases.
Objectives |
The objectives of this study were to determine the best prognostic scoring system, and to create a combined method to predict the prognosis of liver cirrhosis more accurately.
Methods |
We retrospectively reviewed 435 cirrhotic patients from January 2009 to June 2010 and evaluated their short- and medium-term survival. Child-Pugh, MELD and its advanced scoring systems were computed for each patient. The sensitivity and specificity of these scoring systems were analyzed and their validity was assessed using concordance (c)-statistics in predicting the prognosis of cirrhotic patients.
Results |
Overall, 107 patients died within 6 months and 150 patients died within 1 year. The clinical and biochemical characteristics, cirrhosis-related complications, and the scores were significantly different among the survivors and patients who died. The largest area under the receiver operating characteristic curve was 0.741 for the integrated MELD (iMELD) at 6 months and 0.713 for iMELD at 12 months, indicating that iMELD was the best scoring system tested. Given this result, we created a new scoring system that combined iMELD and an index of cirrhosis-related complications, called iMELD-C. This novel system had c indexes of 0.758 for the 6-month survival and 0.746 for the 1-year survival.
Conclusions |
The iMELD-C score is a better predictor of both short- and medium-term survival in patients with cirrhosis.
Le texte complet de cet article est disponible en PDF.Plan
Vol 36 - N° 6
P. 583-591 - décembre 2012 Retour au numéro
Article précédent
- End-stage liver disease: Prevalence, risk factors and clinical characteristics in a cohort of HIV-HCV coinfected Han Chinese
- Liping Deng, Xien Gui, Yong Xiong, Shicheng Gao, Rongrong Yang, Yuping Rong, Jinzhi Hu, Yajun Yan
- Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B
- Zebao He, Jiefei Wang, Kezhou Liu, Haibin Huang, Yao Du, Zongmei Lin, Miaoguo Cai, Xinghua Feng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?